Publications by authors named "Emilio Casanova-Hevia"
Article Synopsis
- JAK1/2 inhibitors are commonly used to treat myeloproliferative neoplasms (MPN), but there have been reports of an increased risk of B-cell non-Hodgkin lymphomas in patients undergoing this treatment.
- In a study of 626 MPN patients, 5.8% of those treated with JAK1/2 inhibitors developed B-cell lymphomas, compared to only 0.36% in patients receiving standard treatments, indicating a significant increase in risk.
- The presence of preexisting B-cell clones in the bone marrow of some patients suggests that early detection could help identify individuals at higher risk for developing these aggressive lymphomas during JAK1/2 therapy.
